Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine

• Main Authors: Rafael León-Montañes, Claudio Trigo-Salado, Eduardo Leo-Carnerero, María Dolores de-la-Cruz-Ramírez, José Manuel Herrera-Justiniano, José Luis Márquez-Galán
• Format: Article
• Language: English
• Published: Aran Ediciones 2013-03-01
• Series: Revista Espanola de Enfermedades Digestivas
• Subjects: Hiperplasia nodular regenerativa; Adalimumab; Azatioprina
• Online Access: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300009&lng=en&tlng=en

Introduction: regenerative nodular hyperplasia (RNH) is a rare liver disease with an etiology that is not well understood. Among the etiological factors are purine-analogue drugs such as azathioprine. Case report: we present a case of a 47-year-old patient diagnosed with Crohn's disease in treatment with azathioprine due to corticosteroid dependency who developed RNH with clinical and laboratory signs of portal hypertension one year after starting treatment. After discontinuation of azathioprine, the patient started treatment and, given the poor disease progression, started treatment with adalimumab. This was continued with an excellent response and without deleterious effects on the liver. Discussion: the relevance of this case is twofold: First, this is a rare and early side effect of azathioprine treatment and this is an irreversible disease with potentially serious complications. Second, because treatment was carried out with biological drugs (adalimumab) despite the patient having advance liver disease with portal hypertension without any evidence of its worsening, nor signs of deleterious effects or complications, given that there is scarce or no experience with adalimumab treatment in this type of situation.